secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-310595
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences reports positive Phase 1 INLIGHT data: WVE-007 reduces visceral fat 9.4%, preserves lean mass
--------------------------------------------------------------------------------

- Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.
- Serum Activin E suppressed up to 78%; durable reductions support once or twice-yearly dosing.
- No severe TEAEs, no discontinuations, no clinically meaningful changes in lipids or liver function.
- Phase 2 planning for monotherapy, add-on to incretins, and maintenance post-incretin therapy.
- Next data: Q1 2026 6-month follow-up from 240 mg cohort and 3-month from 400 mg cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525310595/0001193125-25-310595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525310595/d20484d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-310595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer